Sparrow Ascent
Commercial- Indications
- Opioid withdrawal
Company intelligence / Profile preview
Spark Biomedical’s Sparrow Therapy System is FDA-cleared and commercially available for alleviating symptoms of opioid withdrawal in adults. The company has completed enrollment in a pivotal phase II clinical trial (“SPROUT”) evaluating its tAN platform for treating Neonatal Opioid Withdrawal Syndrome, with long-term follow-up ongoing. Early results have led to Breakthrough Device Designation from the FDA, and the company plans to seek further approvals as data matures
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Spark Biomedical.